Free Trial

Matinas Biopharma (MTNB) Competitors

Matinas Biopharma logo
$0.93 -0.02 (-2.09%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$0.93 0.00 (-0.23%)
As of 07/25/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MTNB vs. MRKR, RVPH, RLMD, BLRX, LEXX, IXHL, RLYB, ASBP, VYNE, and PASG

Should you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include MARKER THERAPEUTICS (MRKR), Reviva Pharmaceuticals (RVPH), Relmada Therapeutics (RLMD), BioLineRx (BLRX), Lexaria Bioscience (LEXX), Incannex Healthcare (IXHL), Rallybio (RLYB), Aspire Biopharma (ASBP), VYNE Therapeutics (VYNE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

Matinas Biopharma vs. Its Competitors

MARKER THERAPEUTICS (NASDAQ:MRKR) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

MARKER THERAPEUTICS has higher revenue and earnings than Matinas Biopharma. MARKER THERAPEUTICS is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MARKER THERAPEUTICS$6.59M2.68-$10.73M-$1.33-1.17
Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.24

22.4% of MARKER THERAPEUTICS shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 14.5% of MARKER THERAPEUTICS shares are held by company insiders. Comparatively, 4.6% of Matinas Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Matinas Biopharma has a net margin of 0.00% compared to MARKER THERAPEUTICS's net margin of -224.46%. MARKER THERAPEUTICS's return on equity of -101.87% beat Matinas Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
MARKER THERAPEUTICS-224.46% -101.87% -83.02%
Matinas Biopharma N/A -123.06%-94.28%

MARKER THERAPEUTICS has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

In the previous week, MARKER THERAPEUTICS had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for MARKER THERAPEUTICS and 0 mentions for Matinas Biopharma. MARKER THERAPEUTICS's average media sentiment score of 0.94 beat Matinas Biopharma's score of 0.00 indicating that MARKER THERAPEUTICS is being referred to more favorably in the media.

Company Overall Sentiment
MARKER THERAPEUTICS Positive
Matinas Biopharma Neutral

MARKER THERAPEUTICS presently has a consensus price target of $13.17, suggesting a potential upside of 744.02%. Given MARKER THERAPEUTICS's stronger consensus rating and higher possible upside, equities research analysts clearly believe MARKER THERAPEUTICS is more favorable than Matinas Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MARKER THERAPEUTICS
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50
Matinas Biopharma
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

MARKER THERAPEUTICS beats Matinas Biopharma on 14 of the 16 factors compared between the two stocks.

Get Matinas Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTNB vs. The Competition

MetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$4.73M$786.26M$5.70B$21.04B
Dividend YieldN/A4.84%4.58%3.59%
P/E Ratio-0.191.4428.4128.45
Price / SalesN/A25.35432.3171.70
Price / CashN/A19.5636.2222.92
Price / Book0.216.918.674.68
Net Income-$22.94M-$4.17M$3.25B$995.51M
7 Day Performance-3.11%1.01%4.25%1.65%
1 Month Performance-1.26%3.65%10.51%4.54%
1 Year PerformanceN/A9.83%35.68%10.00%

Matinas Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTNB
Matinas Biopharma
N/A$0.93
-2.1%
N/AN/A$4.73MN/A-0.1930
MRKR
MARKER THERAPEUTICS
4.5775 of 5 stars
$1.53
-10.0%
$13.17
+760.6%
-70.2%$19.24M$6.59M-1.1560Gap Up
High Trading Volume
RVPH
Reviva Pharmaceuticals
3.3771 of 5 stars
$0.40
-1.0%
$9.00
+2,176.8%
-62.6%$19.16MN/A-0.505Positive News
Gap Up
High Trading Volume
RLMD
Relmada Therapeutics
4.8099 of 5 stars
$0.61
+6.4%
$5.00
+714.3%
-84.0%$19.15MN/A-0.2410Positive News
Gap Down
BLRX
BioLineRx
2.7988 of 5 stars
$4.36
-2.5%
$26.00
+496.3%
-87.8%$19.05M$28.94M-0.5040Positive News
LEXX
Lexaria Bioscience
2.2378 of 5 stars
$0.95
+1.0%
$5.00
+423.7%
-68.3%$18.49M$460K-1.427
IXHL
Incannex Healthcare
0.7365 of 5 stars
$0.82
+34.4%
N/A-51.4%$17.95M$10K-0.683News Coverage
Gap Down
High Trading Volume
RLYB
Rallybio
2.8594 of 5 stars
$0.46
+7.5%
$10.00
+2,063.1%
-62.5%$17.89M$640K-0.4240Positive News
ASBP
Aspire Biopharma
N/A$0.41
+14.1%
N/AN/A$17.73MN/A0.00N/ANews Coverage
Analyst Downgrade
Gap Down
VYNE
VYNE Therapeutics
2.934 of 5 stars
$1.21
+4.3%
$6.25
+416.5%
-30.5%$17.64M$500K-1.2230High Trading Volume
PASG
Passage Bio
3.3846 of 5 stars
$5.27
-5.2%
$150.00
+2,746.3%
-57.7%$17.35MN/A-0.26130News Coverage
Positive News
Insider Trade
Gap Up
High Trading Volume

Related Companies and Tools


This page (NYSE:MTNB) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners